Science & Technology
Revolutionizing CAR T-cell Therapy: Enhancing Activity and Persistence of CAR T-cell by Developing a CAR-Enhancer Platform
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44CA298774-01A1
Award Ceiling
$1.3M
Award Floor
$1.3M
Close Date
Jul 31, 2027
503 days leftTotal Funding
$1.3M
Expected Awards
1
Posted Date
Aug 12, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44CA298774-01A1
Description
SBIR Phase Phase II award: "Revolutionizing CAR T-cell Therapy: Enhancing Activity and Persistence of CAR T-cell by Developing a CAR-Enhancer Platform" awarded to Koi Biotherapeutics Inc. in NEWARK, Delaware. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,340,987. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.